Fovinaciclib Citrate

枸橼酸伏维西利

Report date: 2025/07/01 15:57:40
NME

Base Information

Drug NameFovinaciclib Citrate
Drug Alias Name复妥宁FCN-437FCN-437c
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 6Cyclin-dependent kinase 4
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursHR-positive breast cancer +[6] 
Global Approved IndicationsMetastatic breast cancerBreast Neoplasms
Approved Indications in ChinaMetastatic breast cancerBreast Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2025/05/27
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesFochon Pharmaceuticals Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAhon Pharmaceutical Co LtdFochon Pharmaceuticals LtdJinzhou Aohong Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursHR-positive breast cancer +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A